The FDA has granted Fast Track designation to pevifoscorvir sodium, an oral capsid assembly modulator for chronic HBV.

Current therapies for chronic hepatitis B virus (HBV) infection can effectively suppress viral replication but do not achieve a functional or complete cure. Capsid assembly modulators inhibit the ...

– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 ...

Aligos remains eligible for up to $420m in milestones and tiered, high single-digit royalties on Amoytop’s net sales.

– Phase 1b study will evaluate safety, pharmacokinetic and efficacy endpoints in participants with chronic hepatitis B virus infection with interim data expected by the end of 2024 – SOUTH SAN ...

Researchers develop a large dodecahedral structure through the self- assembly of metal ions and peptides, with potential implications in drug delivery systems and molecular transportation. Controlling ...

– In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity with a mean reduction of 2.9 log IU/mL in plasma HBV DNA over 28 days of treatment – – Enrollment in final cohort of 400 mg ...

New hollow dodecahedral shell demonstrates remarkable stability and potential for functionalization and encapsulating macromolecules. (Nanowerk News) Controlling the topology and structure of ...

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity ...